This trial is active, not recruiting.

Condition amyotrophic lateral sclerosis
Treatments far infrared radiation (5μm to 20μm wavelength), far infrared radiation
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date May 2008
End date May 2010
Trial size 7 participants
Trial identifier NCT00673140, GAAD-ALS-CTP1


Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.

This study will investigate the use of far infrared radiation for the control, management and treatment of ALS.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
far infrared radiation (5μm to 20μm wavelength) Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
far infrared radiation
Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.

Primary Outcomes

Therapy for ALS
time frame: 2 years

Secondary Outcomes

Rehabilitation of ALS patients
time frame: 2 Years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patients with ALS Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's Disease
Principal investigator Ken Nedd, M.D.
Description As a motor neuron disease, ALS causes muscle weakness and atrophy throughout the body as both the upper and lower motor neurons degenerate, ceasing to send messages to muscles. Unable to function, the muscles gradually weaken, develop fasciculations (twitches) because of denervation, and eventually atrophy due to that denervation. The patient may ultimately lose the ability to initiate and control all voluntary movement except of the eyes. Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have ALS.
Trial information was received from ClinicalTrials.gov and was last updated in August 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..